Abnormal activation of NF-κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid-derived suppressor cells to shape the immunosuppressive tumor immune microenvironment.

ABSTRACT:

Background

Osimertinib is the first-line treatment for patients with epidermal growth factor receptor (EGFR) mutations, but the treatment options after drug resistance are limited. Previous studies have suggested that EGFR is in an immunosuppressive tumor immune microenvironment (TIME). However, the evolution of TIME after osimertinib resistance and whether this resistance can be overcome by targeting TIME needs to be further investigated.

Methods

The remodeling process and mechanism of TIME during the treatment with osimertinib were studied.

Results

The proportion of EGFR^L858R+T790M mutant tumor immune infiltrating cells was extremely low. Osimertinib treatment transiently triggered inflammatory cells, but several immunosuppressive cells infiltrated after

SUBMITTER: Wang C 

PROVIDER: S-EPMC10317600 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature